Bravo Multinational, Inc. (OTC: BRVO) Announces Launch of My Charity Wireless, powered by Mobile 13
September 10, 2024 13:00 ET
|
Bravo Multinational Incorporated
Bravo Multinational, Inc. (BRVO) Announces Launch of My Charity Wireless, powered by Mobile 13;Paul Teutul Sr. Partners to Promote Company’s First Charity
Lyell Immunopharma Reports Dose-dependent Clinical Activity from Phase 1 Trial of LYL797, a ROR1-targeted CAR-T Cell Product Candidate Enhanced with its Proprietary Anti-exhaustion Technology
June 26, 2024 07:00 ET
|
Lyell Immunopharma, Inc
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date...
Fatty15 Nabs Prestigious 2024 Mindful Award For “Overall Supplement Product of the Year”
June 11, 2024 08:05 ET
|
Mindful Awards
LOS ANGELES, June 11, 2024 (GLOBE NEWSWIRE) -- The 2024 Mindful Awards Program, an independent recognition platform highlighting conscious companies and products that mindfully make waves in the...
Latest] India Electric Vehicle Market Size/Share Worth USD 150.2 Billion by 2032 at a 25.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 25, 2024 15:00 ET
|
Custom Market Insights
Austin, TX, USA, March 26, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “India Electric Vehicle Market Size, Trends and Insights By Propulsion Type...
Lyell Immunopharma to Participate in 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma
November 09, 2023 16:05 ET
|
Lyell Immunopharma, Inc
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies...
Garuda Therapeutics Named “Overall Cell Biology Company of the Year” By BioTech Breakthrough
November 08, 2023 08:03 ET
|
BioTech Breakthrough
LOS ANGELES, Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology...